Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is ...

This year has seen the US FDA approve 45 new chemical or biologic new entities, exceeding last year's tally of 40, and showing a continued resurgence in the pharma sector's R&D productivity.

Significantly more patients achieved the goal with the combination than with the monotherapy regimen (19.6% vs. 9.9%; p =0.002; Figure 2). Note that patients randomized to combination therapy who ...

The combination of dysglycemia and hyperhomocysteinemia synergistically further increasea the risk of heart failure relative to either risk factor alone, with hyperhomocysteinemia contributing more to ...

The body of a local man was recovered from the Klamath River earlier this week.